Core Viewpoint - 基石药业-B (02616) shares rose over 5% in early trading, reaching a peak increase of 7.41% at HKD 7.39, with a trading volume of HKD 54.65 million [1] Group 1: Clinical Research Developments - The company presented preliminary data from its Phase I clinical study of CS2009 (a PD1/VEGF/CTLA-4 trispecific antibody) at the 2025 ESMO conference [1] - Additionally, the design of the Phase Ib clinical study for CS5001 (a ROR1 antibody-drug conjugate) was disclosed [1] Group 2: Shareholder Activity - GIC disclosed on October 13 that it has increased its stake in 基石药业 to 6% [1] - This marks GIC's second significant purchase of the company's shares in less than two months, having previously acquired 80.4 million shares on August 18 for over HKD 630 million [1]
港股异动 | 基石药业-B(02616)早盘涨超7% 公司在2025 ESMO年会首次发表CS2009的I期临床试验数据